首页> 外文期刊>Assay and drug development technologies >Dynamic mass redistribution as a means to measure and differentiate signaling via opioid and cannabinoid receptors.
【24h】

Dynamic mass redistribution as a means to measure and differentiate signaling via opioid and cannabinoid receptors.

机译:动态质量再分布作为通过阿片类药物和大麻素受体测量和区分信号传导的一种手段。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Classically, G protein-coupled receptor activation by a ligand has been viewed as producing a defined response such as activation of a G protein, activation or inhibition of adenylyl cyclase, or stimulation of phospholipase C and/or alteration in calcium flux. Newer concepts of ligand-directed signaling recognize that different ligands, ostensibly acting at the same receptors, may induce different downstream effects, complicating the selection of a screening assay. Dynamic mass redistribution (DMR), a label-free technology that uses light to measure ligand-induced changes in the mass of cells proximate to the biosensor, provides an integrated cellular response comprising multiple pathways and cellular events. Using DMR, signals induced by opioid or cannabinoid agonists in cells transfected with these receptors were blocked by pharmacologically appropriate receptor antagonists as well as by pertussis toxin. Differences among compounds in relative potencies at DMR versus ligand-stimulated GTPgammaS or receptor binding endpoints, suggesting functional selectivity, were observed. Preliminary evidence indicates that inhibitors of intermediate steps in the cell signaling cascade, such as receptor recycling inhibitors, mitogen-activated protein kinase kinase/p38 mitogen-activated protein kinase inhibitors, or cytoskeletal disruptors, altered or attenuated the cannabinoid-induced response. Notable is the finding that mitogen-activated protein kinase kinase 1/2 inhibitors attenuated signaling induced by the cannabinoid type 2 receptor inverse agonist AM630 but not that stimulated by the agonist CP 55,940. Thus, DMR has the potential to not only identify ligands that activate a given G protein-coupled receptor, but also ascertain the signaling pathways engaged by a specific ligand, making DMR a useful tool in the identification of biased ligands, which may ultimately exhibit improved therapeutic profiles.
机译:传统上,配体的 G 蛋白偶联受体激活被认为会产生明确的反应,例如激活 G 蛋白、激活或抑制腺苷酸环化酶,或刺激磷脂酶 C 和/或钙通量改变。配体定向信号转导的新概念认识到,不同的配体,表面上作用于相同的受体,可能会诱导不同的下游效应,使筛选测定的选择复杂化。动态质量重分布 (DMR) 是一种无标记技术,它使用光来测量配体诱导的靠近生物传感器的细胞质量变化,提供包含多种途径和细胞事件的综合细胞反应。使用DMR,转染这些受体的细胞中由阿片类药物或大麻素激动剂诱导的信号被药理学上适当的受体拮抗剂以及百日咳毒素阻断。观察到化合物在DMR与配体刺激的GTPgammaS或受体结合终点的相对效力上的差异,表明功能选择性。初步证据表明,细胞信号转导级联反应中间步骤的抑制剂,如受体回收抑制剂、丝裂原活化蛋白激酶激酶/p38 丝裂原活化蛋白激酶抑制剂或细胞骨架干扰物,改变或减弱了大麻素诱导的反应。值得注意的是,丝裂原活化蛋白激酶激酶 1/2 抑制剂减弱了大麻素 2 型受体反向激动剂 AM630 诱导的信号转导,但未减弱激动剂 CP 55,940 诱导的信号转导。因此,DMR 不仅有可能识别激活给定 G 蛋白偶联受体的配体,而且还有可能确定特定配体参与的信号通路,使 DMR 成为识别偏倚配体的有用工具,最终可能表现出改进的治疗特征。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号